BR0316205A - N-sulfonilaminotiazol - Google Patents

N-sulfonilaminotiazol

Info

Publication number
BR0316205A
BR0316205A BR0316205-2A BR0316205A BR0316205A BR 0316205 A BR0316205 A BR 0316205A BR 0316205 A BR0316205 A BR 0316205A BR 0316205 A BR0316205 A BR 0316205A
Authority
BR
Brazil
Prior art keywords
sulfonylaminothiazole
sulphonylaminotiazol
mides
arylsulfone
thiazolo
Prior art date
Application number
BR0316205-2A
Other languages
English (en)
Inventor
Erwin Paul Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226616A external-priority patent/GB0226616D0/en
Priority claimed from GB0226602A external-priority patent/GB0226602D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0316205A publication Critical patent/BR0316205A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"N-SULFONILAMINOTIAZOL". A presente invenção refere-se a N-(4,5,6,7-tetrahidro-tiazolo¢5,4c!piridin-2-il)-(C~6~,-~18~)arilsulfona midas, onde o átomo de nitrogênio da piridina é substituído, e onde o anel de piridina é opcionalmente em ponte, útil como um produto farmacêutico relacionado a esteróide sulfatase.
BR0316205-2A 2002-11-14 2003-11-13 N-sulfonilaminotiazol BR0316205A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0226616A GB0226616D0 (en) 2002-11-14 2002-11-14 Organic compounds
GB0226602A GB0226602D0 (en) 2002-11-14 2002-11-14 Organic compounds
PCT/EP2003/012707 WO2004043968A1 (en) 2002-11-14 2003-11-13 N-sulfonylaminothiazole

Publications (1)

Publication Number Publication Date
BR0316205A true BR0316205A (pt) 2005-09-27

Family

ID=32313994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316205-2A BR0316205A (pt) 2002-11-14 2003-11-13 N-sulfonilaminotiazol

Country Status (15)

Country Link
US (1) US7291734B2 (pt)
EP (1) EP1562958B1 (pt)
JP (1) JP4551767B2 (pt)
AR (1) AR041952A1 (pt)
AT (1) ATE396192T1 (pt)
AU (1) AU2003288056A1 (pt)
BR (1) BR0316205A (pt)
CA (1) CA2505249A1 (pt)
DE (1) DE60321209D1 (pt)
ES (1) ES2305542T3 (pt)
MY (1) MY135750A (pt)
PE (1) PE20040693A1 (pt)
PT (1) PT1562958E (pt)
TW (1) TWI318212B (pt)
WO (1) WO2004043968A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505079A (ja) * 2004-06-30 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
GB0505539D0 (en) * 2005-03-17 2005-04-27 Novartis Ag Organic compounds
GB0505541D0 (en) * 2005-03-17 2005-04-27 Novartis Ag Organic compounds
US20100204146A1 (en) 2007-09-17 2010-08-12 Preglem S.A. Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
DE2429195A1 (de) 1974-06-18 1976-02-05 Basf Ag 2-amino-pyrazolo eckige klammer auf 3,4-d eckige klammer zu thiazole
GB8333514D0 (en) * 1983-12-16 1984-01-25 Erba Farmitalia Tetrahydrothiazolo(5 4-c)pyridine derivatives
DE3533331A1 (de) * 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CO5261573A1 (es) * 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
JP4266092B2 (ja) 2001-10-09 2009-05-20 第一三共株式会社 ジアミン誘導体

Also Published As

Publication number Publication date
PE20040693A1 (es) 2004-11-23
AU2003288056A1 (en) 2004-06-03
TW200504081A (en) 2005-02-01
PT1562958E (pt) 2008-08-26
US20060247268A1 (en) 2006-11-02
WO2004043968A1 (en) 2004-05-27
ES2305542T3 (es) 2008-11-01
JP2006507321A (ja) 2006-03-02
ATE396192T1 (de) 2008-06-15
EP1562958B1 (en) 2008-05-21
EP1562958A1 (en) 2005-08-17
HK1081541A1 (en) 2006-05-19
JP4551767B2 (ja) 2010-09-29
AR041952A1 (es) 2005-06-01
MY135750A (en) 2008-06-30
DE60321209D1 (de) 2008-07-03
TWI318212B (en) 2009-12-11
CA2505249A1 (en) 2004-05-27
US7291734B2 (en) 2007-11-06

Similar Documents

Publication Publication Date Title
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DK1202733T3 (da) 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
NO20012057L (no) 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
NL300356I1 (nl) 6-mercapto-cyclodextrinederivaten: omkeermiddelen voor geneesmiddel-geindiceerde neuromusculaire blokkade
NO20015667D0 (no) Tiazoloderivater og farmasöytiske sammensetninger inneholdende dem
DK1542997T3 (da) Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
DE60010076D1 (de) Chinolinderivate als antibakterielle mittel
NO20014128L (no) Camptothecinderivater som har antitumoraktivitet
ATE373665T1 (de) Benzo-kondensierte heteroarylamid-derivative von thienopyridinen nützlich als therapeutische agentien, entsprechende pharmazeutische zusammensetzungen, und methoden für ihre verwendung
PT1585548T (pt) Composições e métodos de administração de agentes farmacológicos
DE69906938D1 (de) Glococorticoid selektive entzündungshemmende mittel
ATE230749T1 (de) Glucocorticoid selektive entzündungshemmende mittel
CO5720000A2 (es) Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE69937301D1 (de) Aminosterolderivate und ihre verwendungen
DE60003873D1 (de) Resistzusammensetzungen und Strukturierungsverfahren
NO20040059L (no) Benzo[G]kinolinderivater for behandling av glaukom og myopi
PT1208113E (pt) 17beta-acil-alfa-propinil-11beta-(amino cíclico)arilesteróides e seus derivados com propriedades hormonais antagonistas
TW200504081A (en) N-sulfonylaminothiazole
DK1087973T3 (da) Imidazotriazolopyrimidiner som lægemiddel med adenosinantagonist effekt

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.